Thus, NfL may represent the first of several fluid biomarkers with relevance in MS monitoring and prediction; one-day multimodal composite indices could be used to most accurately objectify different components of an individual patient’s disease and inform treatment decisions. The gene discussed is NEFL; the disease is myeloid sarcoma.